Clinical Trial Update: Early Administration of ATG Followed by Cyclophosphamide, Busulfan and Fludarabine Before a Donor Stem Cell Transplant in Patients With Hematological Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating early administration of anti-thymocyte globulin (ATG) followed by cyclophosphamide, busulfan and fludarabine as a conditioning regimen …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leukemia
• Lymphoma
• Multiple Myeloma
• Myelodysplastic Myeloproliferative Neoplasms
• Myelodysplastic Syndromes
• Myeloproliferative Neoplasms
• Plasma Cell Neoplasm
• Renal Cell Carcinoma

Drugs mentioned

• BUSULFAN (Busulfan)
• CYCLOPHOSPHAMIDE (Cyclophosphamide)
• Fludarabine (Fludarabine)
• Thymoglobulin (rabbit anti-thymocyte globulin)

Snippet

Sponsor: Northside Hospital, Inc. | Conditions: Myeloproliferative Disorders, Kidney Cancer | Phase 2 | Status: COMPLETED | Results posted: 2012-10-01